 |
|
|
| |
Simeprevir (TMC435) with peginterferon-α2a or -α2b and ribavirin in treatment-naïve HCV genotype 1 patients: QUEST-2, a randomised Phase III trial
|
| |
| |
Reported by Jules Levin
EASL 2013 Amsterdam April 27, 2013
Michael Manns1, Patrick Marcellin2, Fred Poordad3, Evaldo Stanislau Affonso de Araujo4, Maria Buti5, Yves Horsmans6, Ewa Janczewska7, Federico Villamil8, Monika Peeters9, Oliver Lenz9, Sivi Ouwerkerk-Mahadevan10, Ronald Kalmeijer9 and Maria Beumont-Mauviel9
1Medizinische Hochschule Hannover, Hannover, Germany; 2Hopital Beaujon, Clichy, France; 3Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA; 4Hospital das Clinicas of the University of Sao Paulo School of Medicine, University of Sao Paulo, Sao Paulo, Brazil; 5Hospital Vall d'Hebron and Ciberhed del Instituto Carlos III, Barcelona, Spain; 6UCL St Luc, Brussels, Belgium; 7NZOZ Pol-SaNa-Med. Sp z.o.o., Czeladz, Poland; 8CIPREC, Buenos Aires, Argentina; 9Janssen Infectious Diseases BVBA, Beerse, Belgium; 10Janssen Research & Development, Beerse, Belgium
|
| |
|
|
|
|
|
